2.0
May 2, 2013
Recommend
CEO approval
Business Outlook
Pros
Strong financial management and great product performance TODAY
Cons
lack of developmental opportunites Too much exposure to HUMIRA \ Can we get anything to lauch out of our pipeline? Conflicing directions -- be a lean, decisive biopharmaceutical company and yet we just signed a CIA